Enterprise Value
23.06B
Cash
2.312B
Avg Qtr Burn
N/A
Short % of Float
3.21%
Insider Ownership
1.17%
Institutional Own.
98.97%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KRYSTEXXA Details Chronic refractory gout | Approved Quarterly sales | |
Uplizna® (inebilizumab-cdon) Details Inflammatory disease | Approved Quarterly sales | |
TEPEZZA (U.S) Details Eye disease , Thyroid Eye Disease | Phase 3 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details IgG4-related disease | Phase 3 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Neuromuscular disease | Phase 3 Data readout | |
TEPEZZA (OPTIC-J/Japan) Details Eye disease , Thyroid Eye Disease | Phase 3 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Autoimmune disease, Cellulite | Phase 3 Initiation | |
HZN-825 Details IPF (Idiopathic Pulmonary Fibrosis) | Phase 2b Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Kidney Transplant Desensitization | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Cutaneous lupus erythematosus | Phase 2 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
ADX-914 Details Atopic dermatitis | Phase 2 Data readout | |
Dazodalibep (HZN-4920) Details Kidney disease, Lupus nephritis, Autoimmune disease | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Alopecia areata | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Systemic lupus erythematosus | Phase 2 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Rheumatoid arthritis, Autoimmune disease | Phase 2 Update | |
HZN-457 Details Chronic refractory gout | Phase 1 Data readout |